FDA Paves Way for Pfizer/BioNTech's COVID-19 Shot In Young Children

  • In line with the expectations, the FDA has given emergency use authorization to Pfizer Inc PFEBioNTech SE's BNTX COVID-19 vaccine for children 5 through 11 years of age.
  • Related Link: FDA May Clear First COVID-19 Vaccine For Younger Kids, Probably Today: NYT.
  • With this authorization, the Pfizer-BioNTech vaccine is currently the only COVID-19 jab available in the U.S. for use in this age group.
  • The vaccine must be administered in a two-dose regimen of 10-µg doses given 21 days apart for this age group.
  • The authorization is supported by clinical data showing a favorable safety profile and high vaccine efficacy of 90.7% in children 5 through 11 years of age.
  • The companies will begin shipping 10-µg pediatric doses immediately.
  • The CDC's Advisory Committee will meet next week to discuss a potential recommendation for the use and rollout of the vaccine to younger kids.
  • Initial data from the other two age cohorts (2 to 5 years and six months - 2 years) are expected in Q4 of 2021 or Q1 of 2022.
  • Related content: FDA Delays Approval For Moderna's COVID-19 Shot In Teenagers: What You Need To Know
  • Price Action: PFE shares are up 0.62% at $44.01, and BNTX stock is down 0.08% at $278.51 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareFDAGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!